Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Fmr Llc Sells 290,912 Shares of Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $3.66 on Friday. The stock has a market cap of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45. The firm has a 50-day moving average of $2.40 and a two-hundred day moving average of $4.06. Sana Biotechnology, Inc. has a 1 year low of $1.52 and a 1 year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. Research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, HC Wainwright increased their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Sana Biotechnology by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after purchasing an additional 5,338 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Sana Biotechnology by 2.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock worth $1,056,000 after purchasing an additional 6,823 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology in the 3rd quarter worth about $29,000. Arizona State Retirement System increased its stake in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after buying an additional 9,940 shares in the last quarter. Finally, Stifel Financial Corp acquired a new position in shares of Sana Biotechnology during the third quarter valued at approximately $43,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.